PDK1 and pancreatic neoplasm: PH-427, an AKT/pyruvate dehydrogenase kinase 1 (PDK1) inhibitor, is encapsulated into poly(lactic-co-glycolic acid) (PLGA) NPs (PH-427-PLGA-NPs), and treatment with PH-427-PLGA-NPs reduced the tumor size in a MiaPaCa-2 pancreatic cancer model, indicating that NPs can be efficient drug carriers targeting pancreatic cancer that harbors RAS mutations [73].